ELVN

Enliven Therapeutics, Inc. - Common Stock (ELVN)

About Enliven Therapeutics, Inc. - Common Stock (ELVN)

Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.

Details

Daily high

$16.85

Daily low

$16.06

Price at open

$16.12

52 Week High

$30.03

52 Week Low

$13.30

Market cap

810.0M

Dividend yield

0.00%

Volume

171,768

Avg. volume

359,761

P/E ratio

-8.70

Enliven Therapeutics, Inc. - Common Stock News